Ustekinumab  	Ustekinumab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
psoriasis  	psoriasis  	 NNS	B-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
ustekinumab  	ustekinumab  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
psoriasis  	psoriasis  	 NNS	B-NP
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
main  	main  	 JJ	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
three  	three  	 CD	O
randomised  	randomised  	 NNS	B-NP
controlled  	controlled  	 VBN	I-NP
trials  	trials  	 NNS	I-NP
( 	( 	 -LRB-	O
RCTs 	RCTs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
of  	of  	 IN	O
reasonable  	reasonable  	 JJ	O
methodological  	methodological  	 JJ	B-NP
quality  	quality  	 NN	I-NP
and  	and  	 CC	O
measuring  	measuring  	 VBG	O
a  	a  	 DT	O
range  	range  	 NN	O
of  	of  	 IN	O
clinically  	clinically  	 JJ	O
relevant  	relevant  	 JJ	O
outcomes 	outcomes 	 NNS	O
.  	.  	 .	O
Higher  	Higher  	 JJR	B-NP
proportions  	proportions  	 NNS	I-NP
of  	of  	 IN	I-NP
participants  	participants  	 NNS	I-NP
treated  	treated  	 VBN	O
with  	with  	 IN	O
ustekinumab  	ustekinumab  	 NNS	B-NP
( 	( 	 -LRB-	O
45  	45  	 CD	O
mg  	mg  	 NNS	B-NP
and  	and  	 CC	O
90  	90  	 CD	O
mg 	mg 	 CD	B-NP
)  	)  	 -RRB-	O
than  	than  	 IN	O
with  	with  	 IN	O
placebo  	placebo  	 NN	O
or  	or  	 CC	O
etanercept  	etanercept  	 NNS	B-NP
achieved  	achieved  	 VBD	O
an  	an  	 DT	O
improvement  	improvement  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
Psoriasis  	Psoriasis  	 NNP	B-NP
Area  	Area  	 NNP	I-NP
and  	and  	 CC	I-NP
Severity  	Severity  	 NNP	I-NP
Index  	Index  	 NNP	I-NP
( 	( 	 -LRB-	O
PASI 	PASI 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
75 	75 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
PASI  	PASI  	 NNP	B-NP
75 	75 	 CD	O
)  	)  	 -RRB-	O
after  	after  	 IN	O
12  	12  	 CD	O
weeks 	weeks 	 NNS	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
also  	also  	 RB	O
statistically  	statistically  	 RB	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
favour  	favour  	 NN	O
of  	of  	 IN	O
ustekinumab  	ustekinumab  	 NN	B-NP
over  	over  	 IN	O
placebo  	placebo  	 NN	O
for  	for  	 IN	O
PASI  	PASI  	 NNP	B-NP
50  	50  	 CD	O
and  	and  	 CC	O
PASI  	PASI  	 NNP	B-NP
90  	90  	 CD	O
results 	results 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
for  	for  	 IN	O
ustekinumab  	ustekinumab  	 NN	B-NP
over  	over  	 IN	O
etanercept  	etanercept  	 NN	B-NP
for  	for  	 IN	I-NP
PASI  	PASI  	 NNP	I-NP
90  	90  	 CD	O
results 	results 	 NNS	O
.  	.  	 .	O
A  	A  	 DT	O
weight-based  	weight-based  	 JJ	O
subgroup  	subgroup  	 JJ	B-NP
dosing  	dosing  	 JJ	O
analysis  	analysis  	 NN	O
for  	for  	 IN	O
each  	each  	 DT	O
trial  	trial  	 NN	O
was  	was  	 VBD	O
presented 	presented 	 VBN	O
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
methodology  	methodology  	 NN	O
was  	was  	 VBD	O
poorly  	poorly  	 RB	O
described  	described  	 VBN	O
and  	and  	 CC	O
no  	no  	 DT	O
statistical  	statistical  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
to  	to  	 TO	O
support  	support  	 VB	O
the  	the  	 DT	O
chosen  	chosen  	 JJ	O
weight  	weight  	 NN	B-NP
threshold  	threshold  	 NN	I-NP
was  	was  	 VBD	O
presented 	presented 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
carried  	carried  	 VBD	O
out  	out  	 RP	O
a  	a  	 DT	O
mixed  	mixed  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
comparison  	comparison  	 NN	I-NP
( 	( 	 -LRB-	O
MTC 	MTC 	 NNP	B-NP
) 	) 	 -RRB-	O
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
appropriateness  	appropriateness  	 NN	B-NP
of  	of  	 IN	O
some  	some  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
methodological  	methodological  	 JJ	B-NP
aspects  	aspects  	 NNS	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
MTC  	MTC  	 NNP	I-NP
is  	is  	 VBZ	O
uncertain 	uncertain 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
was  	was  	 VBD	O
similar  	similar  	 JJ	O
between  	between  	 IN	O
groups  	groups  	 NNS	O
at  	at  	 IN	O
12  	12  	 CD	O
weeks  	weeks  	 NNS	O
and  	and  	 CC	O
withdrawals  	withdrawals  	 NNS	O
due  	due  	 JJ	O
to  	to  	 TO	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
were  	were  	 VBD	O
low  	low  	 JJ	O
and  	and  	 CC	O
less  	less  	 RBR	O
frequent  	frequent  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
ustekinumab  	ustekinumab  	 NN	B-NP
than  	than  	 IN	O
in  	in  	 IN	O
the  	the  	 DT	O
placebo  	placebo  	 NN	O
or  	or  	 CC	O
etanercept  	etanercept  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
statistical  	statistical  	 JJ	B-NP
comparisons  	comparisons  	 NNS	I-NP
were  	were  	 VBD	O
not  	not  	 RB	O
reported 	reported 	 VBD	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
economic  	economic  	 JJ	B-NP
model  	model  	 NN	I-NP
of  	of  	 IN	O
treatments  	treatments  	 NNS	O
for  	for  	 IN	O
psoriasis  	psoriasis  	 VBG	O
compared  	compared  	 VBN	O
ustekinumab  	ustekinumab  	 VBN	O
with  	with  	 IN	O
other  	other  	 JJ	O
biological  	biological  	 JJ	B-NP
therapies 	therapies 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
model  	model  	 NN	O
used  	used  	 VBD	O
a  	a  	 DT	O
reasonable  	reasonable  	 JJ	O
approach 	approach 	 NN	O
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
not  	not  	 RB	O
clear  	clear  	 JJ	O
whether  	whether  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
estimates  	estimates  	 NNS	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
subgroup  	subgroup  	 JJ	B-NP
analysis 	analysis 	 NN	I-NP
,  	,  	 ,	O
used  	used  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
base-case  	base-case  	 JJ	B-NP
analysis 	analysis 	 NN	I-NP
,  	,  	 ,	O
were  	were  	 VBD	O
methodologically  	methodologically  	 JJ	O
appropriate 	appropriate 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
base-case  	base-case  	 JJ	B-NP
incremental  	incremental  	 JJ	I-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
for  	for  	 IN	O
ustekinumab  	ustekinumab  	 FW	B-NP
versus  	versus  	 FW	O
supportive  	supportive  	 JJ	B-NP
care  	care  	 NN	I-NP
was  	was  	 VBD	O
29,587  	29,587  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-year  	life-year  	 NN	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
one-way  	one-way  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
the  	the  	 DT	O
model  	model  	 NN	O
was  	was  	 VBD	O
most  	most  	 RBS	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
hospital  	hospital  	 NN	O
days  	days  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
supportive  	supportive  	 JJ	B-NP
care 	care 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
cost  	cost  	 NN	B-NP
estimate  	estimate  	 NN	I-NP
for  	for  	 IN	O
intermittent  	intermittent  	 CD	O
etanercept  	etanercept  	 CD	B-NP
25  	25  	 CD	O
mg  	mg  	 NNS	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
utility  	utility  	 NN	B-NP
scores  	scores  	 NNS	I-NP
used 	used 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
's  	's  	 POS	O
scenario  	scenario  	 NN	B-NP
analysis  	analysis  	 NN	I-NP
the  	the  	 DT	O
model  	model  	 NN	O
was  	was  	 VBD	O
most  	most  	 RBS	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
price  	price  	 NN	O
of  	of  	 IN	O
ustekinumab  	ustekinumab  	 CD	B-NP
90  	90  	 CD	O
mg 	mg 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
baseline  	baseline  	 JJ	B-NP
weight  	weight  	 NN	I-NP
>  	>  	 CD	O
100  	100  	 CD	O
kg  	kg  	 NNS	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
relative  	relative  	 JJ	B-NP
risk  	risk  	 NN	I-NP
of  	of  	 IN	O
intermittent  	intermittent  	 FW	O
versus  	versus  	 FW	O
continuous  	continuous  	 FW	B-NP
etanercept  	etanercept  	 JJ	I-NP
25  	25  	 CD	O
mg 	mg 	 NNS	B-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
's  	's  	 POS	O
probabilistic  	probabilistic  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
ustekinumab  	ustekinumab  	 NNS	I-NP
had  	had  	 VBD	O
the  	the  	 DT	O
highest  	highest  	 JJS	O
probability  	probability  	 NN	B-NP
of  	of  	 IN	O
being  	being  	 VBG	O
cost-effective  	cost-effective  	 JJ	O
at  	at  	 IN	O
conventional  	conventional  	 JJ	B-NP
NICE  	NICE  	 NNP	I-NP
thresholds 	thresholds 	 NN	I-NP
,  	,  	 ,	O
assuming  	assuming  	 VBG	O
the  	the  	 DT	O
same  	same  	 JJ	O
price  	price  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
45-mg  	45-mg  	 NNP	O
and  	and  	 CC	O
90-mg  	90-mg  	 CD	O
doses 	doses 	 NNS	O
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
doubling  	doubling  	 VBG	O
the  	the  	 DT	O
price  	price  	 NN	O
of  	of  	 IN	O
ustekinumab  	ustekinumab  	 CD	B-NP
90  	90  	 CD	O
mg  	mg  	 NNS	B-NP
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
ustekinumab  	ustekinumab  	 VBG	O
no  	no  	 DT	O
longer  	longer  	 RB	O
dominating  	dominating  	 VBG	O
the  	the  	 DT	O
comparators 	comparators 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
ustekinumab  	ustekinumab  	 NN	I-NP
in  	in  	 IN	O
relation  	relation  	 NN	O
to  	to  	 TO	O
other  	other  	 JJ	O
drugs  	drugs  	 NNS	O
in  	in  	 IN	O
this  	this  	 DT	O
class  	class  	 NN	O
is  	is  	 VBZ	O
uncertain 	uncertain 	 JJ	O
.  	.  	 .	O
Provisional  	Provisional  	 NNP	O
NICE  	NICE  	 NNP	O
guidance  	guidance  	 VBD	O
issued  	issued  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
STA  	STA  	 NNP	B-NP
states  	states  	 NNS	I-NP
that  	that  	 IN	O
ustekinumab  	ustekinumab  	 NN	B-NP
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
treatment  	treatment  	 NN	B-NP
option  	option  	 NN	I-NP
for  	for  	 IN	O
adults  	adults  	 NNS	O
with  	with  	 IN	O
plaque  	plaque  	 JJ	B-NP
psoriasis  	psoriasis  	 NN	I-NP
when  	when  	 WRB	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
criteria  	criteria  	 NNS	O
are  	are  	 VBP	O
met 	met 	 VBN	O
.  	.  	 .	O
Final  	Final  	 JJ	B-NP
guidance  	guidance  	 NN	I-NP
is  	is  	 VBZ	O
anticipated  	anticipated  	 VBN	O
in  	in  	 IN	O
September  	September  	 NNP	O
2009 	2009 	 CD	O
.  	.  	 .	O
